SOVATELTIDE

Sovateltide is a selective endothelin-B (ET_B) receptor agonist developed for its neuroregenerative, neuroprotective, and angiogenic properties. It is a synthetic peptide structurally related to endothelins and has shown potential in treating central nervous system disorders.

Indications

Sovateltide is indicated or under investigation for the treatment of: -Acute ischemic stroke -Hypoxic-ischemic encephalopathy (HIE) -Spinal cord injury (experimental) -Traumatic brain injury (experimental)

Dosage

Adults: -Typical investigational dosage: 0.3 ?g/kg body weight, administered via intravenous (IV) bolus injection in multiple doses across a defined treatment window (e.g., within 24 hours post-stroke onset). Note: Dosage and administration schedule may vary based on clinical protocol. Always refer to current clinical trial or prescribing guidelines.

Contra-Indications

-Known hypersensitivity to sovateltide or any component of the formulation -Use in pregnancy or lactation not recommended due to lack of data -Severe uncontrolled hypertension (use with caution)

Special Precautions

-Monitor for signs of cerebrovascular instability -Use with caution in patients with cardiovascular comorbidities -Not recommended in pediatric populations unless specifically studied -May require dosage adjustment in renal/hepatic impairment (data pending)

Side Effects

Reported or potential adverse effects include: - Mild headache - Transient hypotension or hypertension - Injection site reactions -Nausea or dizziness -Rare: Seizures, allergic reaction

Drug Interactions

- Limited data available - Theoretical interaction with other vasoactive or neuroactive agents - Use caution with other endothelin receptor modulators